Free Trial

Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis

Zentalis Pharmaceuticals logo
$1.52 +0.06 (+3.77%)
As of 11:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)

Key Stats

Today's Range
$1.46
$1.53
50-Day Range
$1.19
$1.99
52-Week Range
$1.01
$5.44
Volume
251,874 shs
Average Volume
1.19 million shs
Market Capitalization
$109.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.20
Consensus Rating
Moderate Buy

Company Overview

Zentalis Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

ZNTL MarketRank™: 

Zentalis Pharmaceuticals scored higher than 33% of companies evaluated by MarketBeat, and ranked 639th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zentalis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.

  • Upside Potential

    Zentalis Pharmaceuticals has a consensus price target of $8.20, representing about 441.3% upside from its current price of $1.52.

  • Amount of Analyst Coverage

    Zentalis Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Zentalis Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($2.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zentalis Pharmaceuticals is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zentalis Pharmaceuticals is -0.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zentalis Pharmaceuticals has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Zentalis Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.33% of the float of Zentalis Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Zentalis Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Zentalis Pharmaceuticals has recently increased by 0.45%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Zentalis Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Zentalis Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.33% of the float of Zentalis Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Zentalis Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Zentalis Pharmaceuticals has recently increased by 0.45%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Zentalis Pharmaceuticals has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.07 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Zentalis Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for ZNTL on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
Receive ZNTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZNTL Stock News Headlines

Musk Warns. Trump Acts. Your Retirement May Depend on It
With Donald Trump back in the White House, many believe an economic revival could be underway — but it also brings new risks for retirement savers. Traditional 401(k)s and IRAs may leave investors more exposed than they realize. That’s why a Trump-backed IRS strategy is gaining attention. It allows everyday Americans to reposition their retirement savings into real assets like gold and silver — offering both protection and potential upside. A new 2025 Wealth Protection Guide explains exactly how it works.tc pixel
Guggenheim Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
See More Headlines

ZNTL Stock Analysis - Frequently Asked Questions

Zentalis Pharmaceuticals' stock was trading at $3.03 at the beginning of 2025. Since then, ZNTL shares have decreased by 50.0% and is now trading at $1.5150.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) announced its earnings results on Wednesday, August, 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.19.

Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Top institutional investors of Zentalis Pharmaceuticals include Acadian Asset Management LLC (3.89%), Opaleye Management Inc. (2.67%), Tybourne Capital Management HK Ltd. (2.05%) and Decheng Capital LLC (1.83%). Insiders that own company stock include Matrix Capital Management Comp, Cam Gallagher, Melissa B Epperly, Diana Hausman, Scott Dunseth Myers, Kimberly Blackwell, Mark Lackner, Vincent Vultaggio, Jan Skvarka, David Michael Johnson, Carrie Brownstein, Ingmar Bruns and Kevin D Bunker.
View institutional ownership trends
.

Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Home Depot (HD), Chevron (CVX) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
8/06/2025
Today
9/11/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZNTL
CIK
1725160
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$2.20
Potential Upside/Downside
+461.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$165.84 million
Net Margins
N/A
Pretax Margin
-245.74%
Return on Equity
-51.62%
Return on Assets
-40.28%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.99
Quick Ratio
7.99

Sales & Book Value

Annual Sales
$67.43 million
Price / Sales
1.56
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.73 per share
Price / Book
0.31

Miscellaneous

Outstanding Shares
72,140,000
Free Float
70,764,000
Market Cap
$105.32 million
Optionable
Optionable
Beta
1.76

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:ZNTL) was last updated on 9/11/2025 by MarketBeat.com Staff
From Our Partners